Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee

PHASE3RecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

February 1, 2028

Study Completion Date

August 1, 2032

Conditions
Peripheral Artery DiseaseCritical Limb Ischemia
Interventions
DRUG

Temsirolimus

0.1 mg/mL temsirolimus, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be delivered in control participants.

DRUG

Saline placebo

Saline placebo, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be delivered in control participants.

Trial Locations (2)

70360

RECRUITING

Cardiovascular Institute of the South, Houma

75235

RECRUITING

UT Southwestern, Dallas

Sponsors
All Listed Sponsors
lead

Mercator MedSystems, Inc.

INDUSTRY

NCT04433572 - Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee | Biotech Hunter | Biotech Hunter